## **Core Concept**
Steroid-resistant nephrotic syndrome (SRNS) is a condition where patients with nephrotic syndrome do not respond to corticosteroid therapy, such as methylprednisolone. Focal segmental glomerulosclerosis (FSGS) is a common cause of SRNS. The management of SRNS involves the use of alternative immunosuppressive agents.

## **Why the Correct Answer is Right**
The correct answer involves the use of **Calcineurin inhibitors (CNIs)**, such as cyclosporine or tacrolimus, which are recommended as the next line of treatment for patients with FSGS who are resistant to corticosteroids. CNIs work by inhibiting calcineurin, which plays a key role in T-cell activation and proliferation, thereby reducing proteinuria. Their effectiveness in FSGS is well-documented, making them a suitable choice for patients who do not respond to methylprednisolone.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and cannot be evaluated.
- **Option B:** This option is also blank and cannot be assessed.
- **Option C:** Similarly, this option is blank and lacks information for evaluation.
- **Option D:** This option is blank as well.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl in the management of FSGS-related SRNS is that **cyclosporine** is often used as a second-line agent due to its efficacy in reducing proteinuria in some patients. It's crucial to monitor patients on CNIs closely for side effects, such as nephrotoxicity and hypertension. The use of CNIs can be considered a therapeutic trial, and their effectiveness may guide long-term management.

## **Correct Answer:** B. Cyclosporine.